常染色体显性阿尔茨海默病的γ-分泌酶活性、临床特征与生物标志物:显性遗传阿尔茨海默病网络观察性研究(DIAN-OBS)的横断面与纵向分析
基于DIAN-OBS中190例PSEN1致病变异携带者,评估变异对γ-分泌酶活性(GSC)的影响与发病年龄及生物标志物的关联。GSC较低与发病年龄更早相关(r=0.58,p<0.0001),并与MMSE、CDR-SB、WMS-R逻辑记忆延迟回忆评分及PiB-PET、海马体积、CSF标志物变化轨迹相关。作者认为PSEN1变异对γ-分泌酶活性的不同影响可部分解释临床异质性。
要点
- GSC较低与发病年龄更早相关(r=0.58,p<0.0001)。
- GSC与MMSE(β=0.08,p=0.0043)、CDR-SB(-0.05,p=0.0027)、WMS-R逻辑记忆延迟回忆(0.09,p=0.0006)相关。
- GSC较低与PiB-PET信号更快增加、海马体积更快下降相关。
核心结论
- PSEN1变异对γ-分泌酶活性和淀粉样β产生的影响可至少部分解释常染色体显性阿尔茨海默病的临床异质性。
- 研究结果支持以γ-分泌酶为治疗靶点,并提示基于细胞的模型可用于改进症状发病预测。
研究设计与样本
- 横断面与纵向分析,使用DIAN-OBS数据冻结版本15(数据收集于2008年2月29日至2020年6月30日)。
- 数据来自欧洲、北美和南美、亚洲及大洋洲的20个研究站点。
- 纳入190例有可用遗传、临床、影像和CSF数据的PSEN1致病变异携带者。
- PSEN1变异通过基因修饰的PSEN1和PSEN2双敲除人胚肾293T细胞及Aβ37、Aβ38、Aβ40、Aβ42、Aβ43免疫分析进行表征。
- 计算每个变异的γ-分泌酶活性综合评分(GSC),并与临床病史衍生的发病年龄进行相关分析;使用线性混合效应模型评估GSC与多模态生物标志物及临床数据的关联。
主要发现
- 190例携带者中位年龄39.0岁(IQR 32.0–48.0),发病年龄44.5岁(40.6–51.4);女性109例(57%),男性81例(43%)。
- GSC较低(即γ-分泌酶活性低于野生型PSEN1)与发病年龄更早相关(r=0.58;p<0.0001)。
- GSC与MMSE(β=0.08,SE 0.03;p=0.0043)、CDR-SB(-0.05,0.02;p=0.0027)、WMS-R逻辑记忆延迟回忆评分(0.09,0.02;p=0.0006)相关。
- GSC较低与PiB-PET信号更快增加(p=0.0054)、海马体积更快下降(4.19,0.77;p<0.0001)、MMSE更快下降(0.02,0.01;p=0.0020)、WMS-R逻辑记忆延迟回忆更快下降(0.004,0.001;p=0.0003)相关。
临床怎么用
- 作者认为PSEN1变异对γ-分泌酶活性的不同影响可至少部分解释常染色体显性阿尔茨海默病的临床异质性。
- 作者认为研究结果支持以γ-分泌酶为治疗靶点。
- 作者建议基于细胞的模型可用于改进症状发病预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genetic variants that cause autosomal dominant Alzheimer's disease are highly penetrant but vary substantially regarding age at symptom onset (AAO), rates of cognitive decline, and biomarker changes. Most pathogenic variants that cause autosomal dominant Alzheimer's disease are in presenilin 1 (PSEN1), which encodes the catalytic core of γ-secretase, an enzyme complex that is crucial in production of amyloid β. We aimed to investigate whether the heterogeneity in AAO and biomarker trajectories in carriers of PSEN1 pathogenic variants could be predicted on the basis of the effects of individual PSEN1 variants on γ-secretase activity and amyloid β production. METHODS: For this cross-sectional and longitudinal analysis, we used data from participants enrolled in the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) via the DIAN-OBS data freeze version 15 (data collected between Feb 29, 2008, and June 30, 2020). The data freeze included data from 20 study sites in research institutions, universities, hospitals, and clinics across Europe, North and South America, Asia, and Oceania. We included individuals with PSEN1 pathogenic variants for whom relevant genetic, clinical, imaging, and CSF data were available. PSEN1 pathogenic variants were characterised via genetically modified PSEN1 and PSEN2 double-knockout human embryonic kidney 293T cells and immunoassays for Aβ37, Aβ38, Aβ40, Aβ42, and Aβ43. A summary measure of γ-secretase activity (γ-secretase composite [GSC]) was calculated for each variant and compared with clinical history-derived AAO using correlation analyses. We used linear mixed-effect models to assess associations between GSC scores and multimodal-biomarker and clinical data from DIAN-OBS. We used separate models to assess associations with Clinical Dementia Rating Sum of Boxes (CDR-SB), Mini-Mental State Examination (MMSE), and Wechsler Memory Scale-Revised (WMS-R) Logical Memory Delayed Recall, [11C]Pittsburgh compound B (PiB)-PET and brain glucose metabolism using [18F] fluorodeoxyglucose (FDG)-PET, CSF Aβ42-to-Aβ40 ratio (Aβ42/40), CSF log10 (phosphorylated tau 181), CSF log10 (phosphorylated tau 217), and MRI-based hippocampal volume. FINDINGS: Data were included from 190 people carrying PSEN1 pathogenic variants, among whom median age was 39·0 years (IQR 32·0 to 48·0) and AAO was 44·5 years (40·6 to 51·4). 109 (57%) of 190 carriers were female and 81 (43%) were male. Lower GSC values (ie, lower γ-secretase activity than wild-type PSEN1) were associated with earlier AAO (r=0·58; p<0·0001). GSC was associated with MMSE (β=0·08, SE 0·03; p=0·0043), CDR-SB (-0·05, 0·02; p=0·0027), and WMS-R Logical Memory Delayed Recall scores (0·09, 0·02; p=0·0006). Lower GSC values were associated with faster increase in PiB-PET signal (p=0·0054), more rapid decreases in hippocampal volume (4·19, 0·77; p<0·0001), MMSE (0·02, 0·01; p=0·0020), and WMS-R Logical Memory Delayed Recall (0·004, 0·001; p=0·0003). INTERPRETATION: Our findings suggest that clinical heterogeneity in people with autosomal dominant Alzheimer's disease can be at least partly explained by different effects of PSEN1 variants on γ-secretase activity and amyloid β production. They support targeting γ-secretase as a therapeutic approach and suggest that cell-based models could be used to improve prediction of symptom onset. FUNDING: US National Institute on Aging, Alzheimer's Association, German Center for Neurodegenerative Diseases, Raul Carrea Institute for Neurological Research, Japan Agency for Medical Research and Development, Korea Health Industry Development Institute, South Korean Ministry of Health and Welfare, South Korean Ministry of Science and ICT, and Spanish Institute of Health Carlos III.
引用
- Schultz SA, Liu L, Schultz AP, et al. γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol. 2024. PMID: 39074479. doi:10.1016/S1474-4422(24)00236-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。